Overview

Dovitinib in Adenoid Cystic Carcinoma

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital